A synthetic oxazolidinone antimicrobial for treatment of serious gram- positive infections

Formulary

Volumn 35, Issue 6, 2000, Pages 483-497

  Cupo Abbott, Jennifer ^a   Louie, Stan G ^b   Rho, Jay P ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

LINEZOLID; OXAZOLIDINONE DERIVATIVE;

BACTERIAL INFECTION; DIARRHEA; DRUG EFFECT; DRUG FORMULATION; DRUG TOLERANCE; GRAM POSITIVE BACTERIUM; HEADACHE; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NAUSEA; PROTEIN SYNTHESIS INHIBITION; REVIEW; TREATMENT INDICATION;

EID: 0034045452     PISSN: 1082801X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (31)

1. Leclercq R, Derlot E, Duval J, et al. Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium. N Engl J Med 1988;319:157-61.
2. Food and Drug Administration. FDA approves Zyvox, the first antimicrobial drug in a new class. Rockville, MD: National Press Office; April 19, 2000. Talk Paper T00-17.
3. Zyvox (linezolid) package insert. Kalamazoo, MI: Pharmacia & Upjohn; April 2000.
4. Slee AM, Wuonola MA, McRipley RJ, et al. Oxazolidinones, a new class of synthetic antibacterial agents: In vitro and in vivo activities of DuP 105 and DuP 721. Antimicrob Agents Chemother 1987;31:1791-7.
5. Swaney SM, Aoki H, Ganoza MC, Shinabarger DL. The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria. Antimicrob Agents Chemother 1998;42;3251-5.
6. Zurenko GE, Yagi BH, Schaadt RD, et al. In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents. Antimicrob Agents Chemother 1996;40:839-45.
7. Kaatz GW, Seo SM. In vitro activities of oxazolidinone compounds U100592 and U100766 against Staphylococcus aureus and Staphylococcus epidermidis. Antimicrob Agents Chemother 1996;40:799-801.
8. Jorgensen JH, McElmeel ML, Trippy CW. In vitro activities of the oxazolidinone antibiotics U-100592 and U-100766 against Staphylococcus aureus and coagulase-negative Staphylococcus species. Antimicrob Agents Chemother 1997;41:465-7.
9. Jones RN, Pfaller MA, Erwin ME, et al. Antimicrobial activity of linezolid (formerly U-100766) tested against 3,808 strains of gram-positive organisms having resistance to various drugs. Presented at: 37th Annual Meeting of the Infectious Diseases Society of America; November 18-21, 1999; Philadelphia, PA. Abstract P97.
10. Mason EO Jr, Lamberth LB, Kaplan SL. In vitro activities of oxazolidinones U-100592 and U-100766 against penicillin-resistant and cephalosporin-resistant strains of Streptococcus pneumoniae. Antimicrob Agents Chemother 1996;40:1039-40.
11. Spangler SK, Jacobs MR, Appelbaum PC. Activities of RPR 106972 (a new oral streptogramin), cefditoren (a new oral cephalosporin), two new oxazolidinones (U-100592 and U-100766), and other oral and parenteral agents against 203 penicillin-susceptible and -resistant pneumococci. Antimicrob Agents Chemother 1996;40:481-4.
12. Eliopoulos GM, Wennersten CB, Gold HS, Moellering RC Jr. In vitro activities of new oxazolidinone antimicrobial agents against enterococci. Antimicrob Agents Chemother 1996;40:1945-7.
13. Rybak MJ, Cappelletty DM, Moldovan T, et al. Comparative in vitro activities and postantibiotic effects of the oxazolidinone compounds eperezolid (PNU-100592) and linezolid (PNU-100766) versus vancomycin against Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus faecalis, and Enterococcus faecium. Antimicrob Agents Chemother 1998;42:721-4.
14. Noskin GA, Siddiqui F, Stosor V, et al. In vitro activities of linezolid against important gram-positive bacterial pathogens including vancomycin-resistant enterococci. Antimicrob Agents Chemother 1999;43:2059-62
15. Goldstein EJC, Citron DM, Merriam CV. Linezolid activity compared to those of elected macrolides and other agents against aerobic and anaerobic pathogens isolated from soft tissue bite infections in humans. Antimicrob Agents Chemother 1999;43:1469-74.
16. Biedenbach DJ, Jones RN. Disk diffusion test interpretive criteria and quality control recommendations for testing linezolid (U-100766) and eperezolid (U-100592) with commercially prepared reagents. J Clin Microbiol 1997;35:3198-202.
17. Jones RN, Johnson DM, Erwin ME. In vitro antimicrobial activities and spectra of U-100592 and U-100766, two novel fluorinated oxazolidinones. Antimicrob Agents Chemother 1996;40:720-6.
18. Peters J, Kondo KL, Lee RK, et al. In vitro activity of oxazolidinones against Mycobacterium avium complex. J Antimicrob Chemother 1995;35:675-9.
19. Stalker DJ, Wajszczuk CP, Batts DH. Line-zolid safety, tolerance and pharmacokinetics following oral dosing twice daily for 14.5 days. Presented at: 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 1997; Washington, DC. Abstract A-115.
20. 14C]PNU-100766 to healthy volunteers. Presented at: 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 1998; San Diego, CA. Abstract A-53.
21. Brier ME, Stalker DJ, Aronoff GR, et al. Pharmacokinetics of linezolid in subjects with varying degrees of renal function and on dialysis. Presented at: 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 1998; San Diego, CA. Abstract A-54.
22. Stalker DJ, Wajszczuk CP, Batts DH. Linezolid safety, tolerance and pharmacokinetics after intravenous dosing twice daily for 7.5 days. Presented at: 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 1997; Washington, DC. Abstract A-116.
23. Birmingham MC, Zimmer GS, Hafkin B, et al. Outcomes with linezolid from an ongoing compassionate use trial of patients with significant, resistant, gram-positive infections. Presented at: 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 1999; San Francisco, CA. Abstract 1098.
24. Antony SJ, Bitter KM, Moreland T, et al. Methicillin-resistant Staphylococcus aureus infection in a renal allograft recipient treated successfully with a novel new antimicrobial agent (linezolid): New treatment options for infections due to resistant organisms. Clin Infect Dis 1999;29:1341-2.
25. Noskin GA, Siddiqui F, Stosor V, et al. Successful treatment of persistent vancomycin-resistant Enterococcus faecium bacteremia with linezolid and gentamicin. Clin Infect Dis 1999;28:689-90.
26. Noskin GA, Siddiqui F, Stosor V, et al. Linezolid for the treatment of vancomycin-resistant enterococci (VRE) in immunocompromised hosts. Presented at: 37th Annual Meeting of the Infectious Diseases Society of America; November 1999; Philadelphia, PA. Abstract P133.
27. Chien JW, Kucia ML, Salata RA. Use of linezolid, an oxazolidinone, in the treatment of multidrug-resistant gram-positive bacterial infections. Clin Infect Dis 2000;30:146-51.
28. Wilks NE, McConnell-Martin MA, Oliphant TH, Batts DH. Safety and tolerance of linezolid in phase II trials. Presented at: 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 1999; San Francisco, CA. Abstract 1763.
29. Hyatt JM, Ballow CH, Forrest A, et al. Safety and efficacy of linezolid (PNU-100766) in eradication of nasal Staphylococcus aureus. Presented at: 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 1998, San Diego, CA. Abstract A-4.
30. Martin JP, Herberg JT, Slatter JG, Dupuis MJ. Although a novel microtiter-plate assay demonstrates that linezolid (PNU-100766) is a weak, competitive (reversible) inhibitor of human monoamine oxidase A (MAO A), no clinical evidence of MAO A inhibition in phase II or III clinical trials has been observed. Presented at: 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 1998; San Diego, CA. Abstract A-85.
31. Mulazimoglu L, Drenning SD, Yu VL. In vitro activities of two novel oxazolidinones (U100592 and U100766), a new fluoroquinolone (trovafloxacin), and dalfopristinquinupristin against Staphylococcus aureus and Staphylococcus epidermidis. Antimicrob Agents Chemother 1996;40:2428-30. F